Tiziana Life Sciences Ltd

NasdaqCM:TLSA Stock Report

Market Cap: US$115.1m

Tiziana Life Sciences Future Growth

Future criteria checks 0/6

Tiziana Life Sciences's earnings are forecast to decline at 45.7% per annum while its annual revenue is expected to grow at 75% per year. EPS is expected to decline by 44.8% per annum.

Key information

-45.7%

Earnings growth rate

-44.81%

EPS growth rate

Biotechs earnings growth29.1%
Revenue growth rate75.0%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Sep 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Jun 14

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Summary Tiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralumab in early-stage Alzheimer's Disease is set to begin in 2025, targeting microglial activation and neuroinflammation. The global Alzheimer's Disease market is expected to reach $23.8 billion by 2031. Upcoming catalysts include the Alzheimer's phase 2 trial initiation and a CEO presentation of MS program data at Bio International Convention in June 2025. Read the full article on Seeking Alpha
Seeking Alpha • Dec 24

Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis

Summary Tiziana Life Sciences is developing foralumab, an anti-CD3 monoclonal antibody, for treating neurodegenerative diseases like SPMS and Alzheimer's, with promising early results. Positive Phase 2 trial results in SPMS could attract investor interest due to the large market and lack of approved drugs for non-active SPMS. The company faces financial challenges with high cash burn and potential shareholder dilution despite recent funding efforts and an at-the-market sales agreement. Given the financial risks and pending trial results, I currently rate Tiziana a Hold, awaiting more data from the Phase 2 SPMS trial. Read the full article on Seeking Alpha
Analysis Article • Sep 19

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 03

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 16

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Oct 12

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Tiziana Life Sciences (NASDAQ:TLSA) is trading 11.2% higher premarket after it plans to submit an application to begin Phase 1 trial of intranasal foralumab in Alzheimer's disease. Tiziana plans on filing the Investigational New Drug Application for Alzheimer’s disease by Q3 2023 upon the completion of requested toxicology studies, and will start Phase 1 program by the end of 2023.
Seeking Alpha • Sep 23

Tiziana chief medical officer further increases holdings in company

Matthew Davis, chief medical officer of biotechnology company Tiziana Life Sciences (NASDAQ:TLSA), has purchased 75,000 shares of the company's common stock at $0.83 per share. The transaction increases Davis' total holding in the firm to 175,000 common shares. Earlier this month, Davis bought 100K TLSA shares at $0.76 per share.
Seeking Alpha • Sep 16

Tiziana Life Sciences executive chairman further raises stake in company

Tiziana Life Sciences (NASDAQ:TLSA) has announced a share purchase by its executive chairman, Gabriele Cerrone. Panetta Partners, an entity in which Cerrone has a beneficial interest, purchased 29,318 common shares priced between $0.78 and $0.81 per share. The acquisition raises Cerrone's interests in the firm from 37.70% to 37.72%.
Seeking Alpha • Aug 25

Tiziana executive chairman raises stake in company again, buys more shares

Tiziana Life Sciences (NASDAQ:TLSA) said that its Executive Chairman Gabriele Cerrone bought additional common shares, raising stake in the company to 37.70% from 37.61%. The company added that Panetta Partners, an entity in which Cerrone has a beneficial interest, bought 80K shares at $0.75 apiece. Earlier in August, Tiziana noted that Panetta had bought 20K shares which had raised Cerrone's interest to 37.61%.
Seeking Alpha • Aug 17

Tiziana Life Sciences discloses share purchase by executive chairman

Tiziana Life Sciences (NASDAQ:TLSA) has announced a purchase of 20K common shares by Panetta Partners, an entity in which executive chairman Gabriele Cerrone holds a beneficial interest. The shares were acquired at $0.75 each. The transaction brings Mr Cerrone's interests in the firm from 37.60% to 37.61%.
Analysis Article • Aug 15

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 15

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Tiziana Life Sciences (NASDAQ:TLSA) said on Friday that Kunwar Shailubhai as Chief Executive Officer, Chief Scientific Officer and Board director had resigned, effective as of August 1. The company said Shailubhai resigned due to personal reasons. The company's board has appointed Gabriele Cerrone as interim Chief Executive Officer to lead the Company through the period of transition.

Earnings and Revenue Growth Forecasts

NasdaqCM:TLSA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-23N/A-211
12/31/2027N/A-22N/A-211
12/31/2026N/A-22N/A-262
12/31/2025N/A-18-13-13N/A
9/30/2025N/A-16-11-11N/A
6/30/2025N/A-13-9-9N/A
3/31/2025N/A-12-5-5N/A
12/31/2024N/A-12-2-2N/A
9/30/2024N/A-13-3-3N/A
6/30/2024N/A-14-4-4N/A
3/31/2024N/A-16-10-10N/A
12/31/2023N/A-18-16-16N/A
9/30/2023N/A-19-17-17N/A
6/30/2023N/A-20-19-19N/A
3/31/2023N/A-17-19-19N/A
12/31/2022N/A-15-20-20N/A
9/30/2022N/A-13-20-20N/A
6/30/2022N/A-11-21-21N/A
3/31/2022N/A-17-21-21N/A
12/31/2021N/A-23-22-22N/A
9/30/2021N/A-31-20-20N/A
6/30/2021N/A-38-17-17N/A
3/31/2021N/A-32-14-14N/A
12/31/2020N/A-26-11-11N/A
9/30/2020N/A-18-10-10N/A
6/30/2020N/A-10-8-8N/A
3/31/2020N/A-10-8-8N/A
12/31/2019N/A-9-7-7N/A
9/30/2019N/A-8N/A-7N/A
6/30/2019N/A-8N/A-7N/A
3/31/2019N/A-8N/A-6N/A
12/31/2018N/A-8N/A-5N/A
9/30/2018N/A-8N/A-5N/A
6/30/2018N/A-9N/A-6N/A
3/31/2018N/A-9N/A-7N/A
12/31/2017N/A-9N/A-8N/A
9/30/2017N/A-11N/A-8N/A
6/30/2017N/A-12N/A-9N/A
3/31/2017N/A-10N/A-7N/A
12/31/2016N/A-9N/A-6N/A
9/30/2016N/A-9N/A-6N/A
6/30/2016N/A-9N/A-5N/A
3/31/2016N/A-11N/A-7N/A
12/31/2015N/A-13N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLSA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TLSA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TLSA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TLSA is forecast to have no revenue next year.

High Growth Revenue: TLSA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TLSA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 11:39
End of Day Share Price 2026/09/15 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tiziana Life Sciences Ltd is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG
Elemer PirosLucid Capital Markets